BRY812 for advanced solid tumors that have failed standard therapy
Part of Cancer clinical trials.
This trial tests an experimental drug called BRY812 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective against a protein called LIV-1 found on some cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has not responded to standard treatments or cannot tolerate them.
- You have at least one measurable tumor on a scan.
- Your daily activity level is mostly independent (ECOG 0 or 1).
- You have adequate organ function (kidney, liver, bone marrow) as determined by blood tests.
- You have not had prior treatment that targets the LIV-1 protein.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B16D1 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if this drug is safe and how well it works.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
This trial tests a new drug, BRY812, in women with advanced ovarian, endometrial, or ovarian clear cell cancer whose tumors have a specific marker called LIV-1. The goal is to see if it can shrink tumors or slow their growth.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.